FY2025 · ended Dec 31, 2025 · Revenue $348.97M, +22.2% YoY · Filed Feb 26, 2026
Mannkind Corp (MNKD) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $349.0 million and net income of $5.9 million. Free cash flow was $13.7 million. As of Jun 30, 2026 it held $116.1 million in cash and investments and $330.8 million in total debt.
Revenue (TTM)
$393.63M
+30.5% vs year-ago TTM
Net income (TTM)
$-43.61M
-233.0% vs year-ago TTM
Operating cash flow (TTM)
$-8.05M
-123.3% vs year-ago TTM
Free cash flow (TTM)
$-18.14M
-163.0% vs year-ago TTM
EPS (TTM)
$-0.14
-227.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
308.10M
+1.5% vs prior year
Net cash
$-214.71M
as of Jun 30, 2026
Operating margin
2.3%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MNKD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Danbury, CT
- SEC filer status
- Large accelerated filer
- SEC CIK
- 899460
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $349.0M | $285.5M | $199.0M | $99.8M | $75.4M |
| Operating income | $38.8M | $72.6M | $8.7M | -$64.1M | -$47.0M |
| Net income | $5.9M | $27.6M | -$11.9M | -$87.4M | -$80.9M |
| Diluted EPS | $0.02 | $0.10 | -$0.04 | -$0.34 | — |
| Operating cash flow | $18.3M | $42.5M | $34.1M | -$80.7M | -$61.7M |
| Free cash flow | $13.7M | $32.8M | -$8.3M | -$88.3M | -$73.2M |
| Total assets | $792.2M | $393.8M | $475.2M | $295.3M | $321.2M |
| Total liabilities | $843.2M | $472.7M | $721.4M | $545.8M | $530.5M |
| Stockholders' equity | -$51.0M | -$78.8M | -$246.2M | -$250.5M | -$209.3M |
| Cash and investments | $176.4M | $202.7M | $302.3M | $172.8M | $260.7M |
| Total debt | $367.4M | $50.1M | $378.1M | $384.2M | $382.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Aug 21, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Unregistered share sale, Other events
|
Jul 24, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Other events
|
Jun 2, 2026 | May 29, 2026 |
| 8-K |
Current report
Other events
|
May 28, 2026 | May 27, 2026 |
All 1000 Mannkind Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.